A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer

Exclusion Criteria

• •other malignancy with the exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to the entry of study
• •previously received chemotherapy or therapy with systemic anti-tumor effect
• •significant co-morbid medical conditions, including, but not limited to , heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes
• •fertile women of child-bearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period and for three months following cessation of treatment
• •Presence of mental disease or psychotic manifestation
• •Participation in another clinical trial with any investigational drug within 30 days prior to entry
• •judged ineligible by physicians for participation in the study due to safety concern.